CL2018001548A1 - Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas - Google Patents
Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadasInfo
- Publication number
- CL2018001548A1 CL2018001548A1 CL2018001548A CL2018001548A CL2018001548A1 CL 2018001548 A1 CL2018001548 A1 CL 2018001548A1 CL 2018001548 A CL2018001548 A CL 2018001548A CL 2018001548 A CL2018001548 A CL 2018001548A CL 2018001548 A1 CL2018001548 A1 CL 2018001548A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- liver diseases
- subject
- intrahepatic cholestasis
- related liver
- Prior art date
Links
- 208000001024 intrahepatic cholestasis Diseases 0.000 title 1
- 230000007872 intrahepatic cholestasis Effects 0.000 title 1
- 208000019423 liver disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 206010008635 Cholestasis Diseases 0.000 abstract 2
- 230000007870 cholestasis Effects 0.000 abstract 2
- 231100000359 cholestasis Toxicity 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- 238000005903 acid hydrolysis reaction Methods 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000006345 epimerization reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
LA INVENCIÓN SE DIRIGE A UN MÉTODO PARA TRATAR O REDUCIR EL RIESGO DE COLESTASIS INTRAHEPÁTICA EN UN SUJETO EN NECESIDAD, QUE COMPRENDE ADMINISTRAR AL SUJETO UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE UNA COMPOSICIÓN QUE COMPRENDE AL MENOS UNA ESPECIE O CEPA BACTERIANA QUE COMPRENDE LA ACTIVIDAD DE DESCONJUGACIÓN/HIDRÓLISIS DEL ÁCIDO BILIAR Y/O ACTIVIDAD DE 7- EPIMERIZACIÓN, TRATANDO DE ESTE MODO O REDUCIENDO EL RIESGO DE COLESTASIS INTRAHEPÁTICA EN UN SUJETO EN NECESIDAD; TAMBIÉN SE PROPORCIONAN LAS COMPOSICIONES PARA USO EN DICHOS MÉTODOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562266771P | 2015-12-14 | 2015-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018001548A1 true CL2018001548A1 (es) | 2018-07-20 |
Family
ID=57570064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018001548A CL2018001548A1 (es) | 2015-12-14 | 2018-06-11 | Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180369297A1 (es) |
| EP (1) | EP3389680B1 (es) |
| JP (2) | JP2018537484A (es) |
| KR (1) | KR20180094950A (es) |
| CN (1) | CN109069548A (es) |
| AU (1) | AU2016374365B2 (es) |
| BR (1) | BR112018012022A2 (es) |
| CA (1) | CA3008195A1 (es) |
| CL (1) | CL2018001548A1 (es) |
| ES (1) | ES2962302T3 (es) |
| IL (1) | IL259480B2 (es) |
| MX (1) | MX2018007227A (es) |
| RU (1) | RU2743405C2 (es) |
| SG (1) | SG11201804255QA (es) |
| WO (1) | WO2017102816A1 (es) |
| ZA (1) | ZA201804660B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| EP2953472A4 (en) | 2012-11-23 | 2017-03-01 | Seres Therapeutics, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| JP2016519664A (ja) | 2013-03-15 | 2016-07-07 | セレス セラピューティクス インコーポレイテッド | ネットワークを基にした微生物組成物及び方法 |
| EP4529950A3 (en) | 2014-10-31 | 2025-08-20 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment |
| US11701394B2 (en) * | 2017-08-14 | 2023-07-18 | Seres Therapeutics, Inc. | Compositions and methods for treating cholestatic disease |
| AU2018326705A1 (en) | 2017-08-30 | 2020-03-05 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
| US12214002B2 (en) | 2017-10-30 | 2025-02-04 | Seres Therapeutics, Inc. | Compositions and methods for treating antibiotic resistance |
| WO2020018949A2 (en) | 2018-07-19 | 2020-01-23 | Pendulum Therapeutics, Inc. | Methods and compositions for microbial engraftment |
| WO2020056298A1 (en) | 2018-09-13 | 2020-03-19 | Assembly Biosciences, Inc. | Methods and compositions for treating gastrointestinal and inflammatory disorders |
| CN112280720B (zh) * | 2020-11-19 | 2021-07-13 | 山东龙昌动物保健品有限公司 | 一株多形拟杆菌gl-02及其与胆汁酸复配的复合菌剂与应用 |
| JP2024506052A (ja) * | 2021-02-08 | 2024-02-08 | リスキュア・バイオサイエンシーズ・カンパニー・リミテッド | ロイコノストック・シトレウム菌株を有効成分として含む胆汁うっ滞性肝疾患の予防または治療用医薬組成物 |
| JPWO2023176952A1 (es) | 2022-03-18 | 2023-09-21 | ||
| GB2628547A (en) * | 2023-03-27 | 2024-10-02 | Univ Newcastle | Probiotic and postbiotic compositions, products and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1283225B1 (it) * | 1996-03-11 | 1998-04-16 | Renata Maria Anna Ve Cavaliere | Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle |
| AU4905300A (en) * | 1999-05-25 | 2000-12-12 | Andrew W. Bruce | Oral administration of lactobacillus for the maintenance of health in women |
| AUPQ899700A0 (en) * | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| MX2008010422A (es) * | 2006-02-15 | 2008-10-27 | Nestec Sa | Uso de bifidobacterium longum para la prevencion y tratamiento de inflamacion. |
| WO2010125421A1 (en) * | 2009-04-30 | 2010-11-04 | Compagnie Gervais Danone | Use of collinsella aerofaciens for reducing bloating |
| CN102539791A (zh) * | 2012-01-09 | 2012-07-04 | 宁波天康生物科技有限公司 | 总胆汁酸的定量测定及测定试剂盒 |
| CA2926466C (en) * | 2013-10-03 | 2021-11-16 | Frederic Bushman | Compositions comprising a defined microbiome and methods of use thereof |
-
2016
- 2016-12-14 IL IL259480A patent/IL259480B2/en unknown
- 2016-12-14 ES ES16812728T patent/ES2962302T3/es active Active
- 2016-12-14 CN CN201680073160.6A patent/CN109069548A/zh active Pending
- 2016-12-14 JP JP2018530858A patent/JP2018537484A/ja active Pending
- 2016-12-14 SG SG11201804255QA patent/SG11201804255QA/en unknown
- 2016-12-14 EP EP16812728.0A patent/EP3389680B1/en active Active
- 2016-12-14 RU RU2018124487A patent/RU2743405C2/ru active
- 2016-12-14 CA CA3008195A patent/CA3008195A1/en active Pending
- 2016-12-14 WO PCT/EP2016/080941 patent/WO2017102816A1/en not_active Ceased
- 2016-12-14 US US15/781,595 patent/US20180369297A1/en not_active Abandoned
- 2016-12-14 MX MX2018007227A patent/MX2018007227A/es unknown
- 2016-12-14 AU AU2016374365A patent/AU2016374365B2/en not_active Expired - Fee Related
- 2016-12-14 BR BR112018012022-7A patent/BR112018012022A2/pt not_active IP Right Cessation
- 2016-12-14 KR KR1020187019268A patent/KR20180094950A/ko not_active Ceased
-
2018
- 2018-06-11 CL CL2018001548A patent/CL2018001548A1/es unknown
- 2018-07-12 ZA ZA2018/04660A patent/ZA201804660B/en unknown
-
2022
- 2022-07-28 JP JP2022120558A patent/JP2022166039A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016374365A1 (en) | 2018-07-12 |
| ZA201804660B (en) | 2022-12-21 |
| IL259480B1 (en) | 2023-05-01 |
| EP3389680B1 (en) | 2023-10-11 |
| RU2743405C2 (ru) | 2021-02-18 |
| WO2017102816A1 (en) | 2017-06-22 |
| MX2018007227A (es) | 2018-08-01 |
| IL259480B2 (en) | 2023-09-01 |
| JP2018537484A (ja) | 2018-12-20 |
| IL259480A (en) | 2018-07-31 |
| CA3008195A1 (en) | 2017-06-22 |
| RU2018124487A (ru) | 2020-01-10 |
| US20180369297A1 (en) | 2018-12-27 |
| RU2018124487A3 (es) | 2020-05-29 |
| BR112018012022A2 (pt) | 2018-12-04 |
| JP2022166039A (ja) | 2022-11-01 |
| AU2016374365B2 (en) | 2023-04-13 |
| CN109069548A (zh) | 2018-12-21 |
| EP3389680A1 (en) | 2018-10-24 |
| EP3389680C0 (en) | 2023-10-11 |
| KR20180094950A (ko) | 2018-08-24 |
| ES2962302T3 (es) | 2024-03-18 |
| SG11201804255QA (en) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001548A1 (es) | Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas | |
| ECSP21001547A (es) | Formulación farmacéutica de odevixibat | |
| MX2019007586A (es) | Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares. | |
| PH12019501323A1 (en) | Compositions comprising sulfated polysaccharides | |
| CL2019000304A1 (es) | Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento. | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| GEP20217328B (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| MX381283B (es) | Tratamiento de pénfigo. | |
| PE20170904A1 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
| MX390954B (es) | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| EA201890859A1 (ru) | Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот | |
| BR112015029240A2 (pt) | composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| MX395231B (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. | |
| MX2018004132A (es) | Método de tratamiento de meduloblastoma con un inhibidor de ezh2. | |
| MX2019007161A (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| BR112017018758A2 (pt) | alteração do metabolismo de esteroide para tratamento de doença dependente de esteroide | |
| BR112019006880A2 (pt) | compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos | |
| EA201792341A1 (ru) | Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap) | |
| EA201990560A1 (ru) | Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии | |
| EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида |